Single-centre retrospective review of dupilumab-induced ocular surface disease in an Australian adult cohort with moderate-to-severe atopic dermatitis.

Abstract

Treatment and management outcomes or patients with atopic dermatitis has significantly improved with the inclusion of dupilumab into the pharmaceutical benefits scheme, as a safe and effective treatment. Ocular surface disease remains one of the most frequent adverse events seen with dupilumab, and impacts quality of life and can interrupt treatment. This retrospective review aims to further characterise the experience and risk factors of dupilumab-induced ocular surface disease to inform management and support long-term use for patients, improving overall treatment outcomes.